AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 39 analysts
Fundamentals
Fundamentals institutional score is 18 using EVA spread proxy -3.2%; growth durability 0.0.
Valuation
Valuation institutional score is 59 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 40 using mean target upside 9.2%; dispersion penalty 22.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 92 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 5 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. technical structure and market sentiment provide support, while fundamentals and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 5.0% below historical median. Valuation is stable — currently in the strongly undervalued zone (z-score: -0.64). Confidence: 93%.
Live forward EPS implies next-12-month EPS of ₹59.39. Applying the stock's normalized valuation corridor produces a fair range of ₹1,734.19 to ₹1,913.55, with base value near ₹1,843.47 (+59.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹59.39
Forward P/E
19.5x
Base Fair Value
₹1,843.47
Fair Range
₹1,734.19 - ₹1,913.55
Upside To Base
+59.1%
Estimate Source
Live forward EPS
Growth Estimate
-68.7%
5Y Average
27.45
Current
29.50
Overvalued
32.22
Undervalued
29.20
5Y Average
16.51
Current
17.54
Overvalued
18.94
Undervalued
13.54
5Y Average
2.74
Current
2.91
Overvalued
3.15
Undervalued
2.33
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -23% vs avg | -2.7% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.0x Premium | +44% vs avg | +23.2% |
CG POWER AND IND SOL LTD CGPOWERHeavy Electrical Equipments | +14.0% | 9.8% | 111.1x Premium | +143% vs avg | +32.2% |
HINDALCO INDUSTRIES LTD HINDALCOMetals - Aluminium | +32.1% | 5.5% | 14.3x Undervalued | -69% vs avg | +57.5% |
HCL TECHNOLOGIES LTD HCLTECHIT Services & Consulting | +3.0% | 13.0% | 21.1x Undervalued | -54% vs avg | -8.8% |
BAJAJ AUTO LIMITED BAJAJ-AUTOTwo Wheelers | +64.0% | 16.3% | 27.7x Undervalued | -39% vs avg | +40.9% |
EICHER MOTORS LTD EICHERMOTTrucks & Buses | +31.5% | 23.2% | 38.0x Undervalued | -17% vs avg | +41.4% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 52.3x Fair | +14% vs avg | +44.3% |
DR. REDDY S LABORATORIES trades at a discount (29.2x vs peer avg 45.7x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CIPLA LTD, APOLLO HOSPITALS ENTER. L, CG POWER AND IND SOL LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹5.14K CrJun 2026Latest net profit
₹405 CrJun 2026Latest EPS
₹4.85Jun 2026Net margin
9.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 5,437 | 4,839 | 4,103 | 5,105 | 5,841 | 6,696 | 5,015 | 5,563 | 7,810 | 4,619 | 4,283 | 3,822 | 5,137 |
| Expenses + | 3,210 | 3,210 | 3,447 | 3,726 | 3,888 | 3,975 | 3,823 | 4,120 | 3,972 | 4,138 | 4,183 | 4,322 | 4,689 |
| Operating Profit | 2,228 | 1,629 | 656 | 1,379 | 1,953 | 2,722 | 1,192 | 1,443 | 3,837 | 480 | 100 | -500 | 447 |
| OPM % | 41% | 34% | 16% | 27% | 33% | 41% | 24% | 26% | 49% | 10% | 2.3% | -13% | 9% |
| Other Income + | 234 | 223 | 228 | 213 | 218 | 208 | 235 | 414 | 398 | 364 | 360 | 567 | 440 |
| Interest | 4 | 6 | 6 | 6 | 7 | 28 | 43 | 31 | 19 | 33 | 41 | 54 | 73 |
| Depreciation | 237 | 246 | 246 | 246 | 250 | 260 | 265 | 264 | 280 | 295 | 314 | 318 | 318 |
| Profit before tax | 2,220 | 1,601 | 632 | 1,339 | 1,914 | 2,641 | 1,119 | 1,562 | 3,936 | 516 | 104 | -306 | 497 |
| Tax % | 26% | 25% | 25% | 23% | 26% | 29% | 24% | 23% | 25% | 25% | 13% | -28% | 19% |
| Net Profit + | 1,639 | 1,193 | 475 | 1,035 | 1,417 | 1,882 | 849 | 1,201 | 2,961 | 387 | 91 | -219 | 405 |
| EPS in Rs | 19.69 | 14.30 | 5.70 | 12.41 | 16.99 | 22.56 | 10.18 | 14.39 | 35.48 | 4.64 | 1.09 | -2.63 | 4.85 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).